Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

v3.23.1
CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - CAD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
CURRENT ASSETS:    
Cash and cash equivalents $ 2,449 $ 13,903
Trade receivables 8,684 16,711
Advances to suppliers 1,631 2,300
Other accounts receivable 3,323 14,482
Loans receivable 0 2,708
Biological assets 0 1,687
Inventory 16,585 29,391
Total current assets 32,672 81,182
NON-CURRENT ASSETS:    
Property, plant and equipment, net 5,221 30,268
Investments in affiliates 2,410 2,429
Advance payment for intangible assets of pharmacy 0 3,129
Derivative assets 0 14
Right-of-use assets, net 1,929 18,162
Deferred tax assets, net 763 16
Intangible assets, net 7,910 30,885
Goodwill 9,771 121,303
Total non-current assets 28,004 206,206
Total assets 60,676 287,388
CURRENT LIABILITIES:    
Trade payables 15,312 13,989
Bank loans and others 9,246 9,502
Other accounts payable and accrued expenses 6,013 20,143
Accrued purchase consideration liabilities 2,434 6,039
Current maturities of operating lease liabilities 814 1,554
Total current liabilities 33,819 51,227
NON-CURRENT LIABILITIES:    
Warrants measured at fair value 8 6,022
Operating lease liabilities 1,075 17,820
Long-term loans 399 392
Employee benefit liabilities, net 246 391
Deferred tax liability, net 1,332 6,591
Total non-current liabilities 3,060 31,216
Total liabilities 36,879 82,443
EQUITY ATTRIBUTABLE TO EQUITY HOLDERS OF THE COMPANY:    
Share capital and premium 245,776 237,677
Treasury Stock 0 (660)
Translation reserve 1,283 2,614
Reserve from share-based payment transactions 15,167 12,348
Accumulated deficit (239,574) (50,743)
Total equity attributable to shareholders of the Company 22,652 201,236
Non-controlling interests 1,145 3,709
Total equity 23,797 204,945
Total equity and liabilities $ 60,676 $ 287,388